• Yi Ting Lim, Wee Ming Tay, Zhiwen Joseph Lo, Uei Pua, Lawrence Han Hwee Quek, Bien Ping Tan, Sadhana Chandrasekar, and TanGlenn Wei LeongGWLVascular Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore..
• Vascular Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore.
• Singap Med J. 2022 May 1; 63 (5): 263267263-267.

IntroductionMycotic aortic aneurysm (MAA) is a life-threatening condition. Endovascular repair (EVAR) of aortic aneurysms has been found to be a safe and effective alternative to open repair. We aimed to present the short- to medium-term outcomes for EVAR of MAA in our cohort.MethodsWe conducted a retrospective study of 23 consecutive patients with MAA who underwent EVAR in our hospital from January 2008 to July 2017.ResultsThe mean age of our study population was 62 years. The mean aneurysmal size was 3.2 cm. Abdominal MAAs (n = 16, 70%) were the most common, followed by thoracic MAAs (n = 4, 17%). There was no 30-day mortality in our cohort. Endoleak (Types 1, 3, 4) was detected in 3 (13%) cases. At the one-month surveillance computed tomography aortogram, all patients had a reduction in aneurysmal size and 5 (22%) had complete aneurysmal sac resolution. 7 (30%) patients had sac resolution at six months and 8 (35%) patients, at 12 months. The overall survival was 91%, 80% and 61% at one, 12 and 60 months, respectively.ConclusionEVAR is a feasible and durable method for the repair of MAA, with a five-year overall survival of 61%. All patients in our study had a reduction in aneurysmal size at one month, with 65% having complete aneurysmal sac resolution by 12 months.Copyright: © Singapore Medical Association.

18 keywords...

hide…